Q: What is Ingrezza used for?

Ingrezza is used to treat tardive dyskinesia , chorea associated with Huntington's disease .

Q: How does Ingrezza work?

Mechanism of Action Ingrezza is classified as a vesicular monoamine transporter 2 (VMAT2) inhibitor. It works by blocking a specific protein in the brain called VMAT2, which is responsible for moving certain chemicals into nerve cells. Regulating Brain Chemicals The primary chemical affected by this medication is dopamine. Dopamine is a natural substance that helps the brain control muscle movements. In people with certain movement disorders, there may be an imbalance or overactivity of dopamine in the parts of the brain that manage motor function. By blocking the VMAT2 protein, Ingrezza reduces the amount of dopamine released in the brain. This reduction helps to: Control involuntary, repetitive body movements. Manage jerky or irregular motions associated with chorea. Although the way the drug interacts with the VMAT2 protein is established, the precise mechanism by which it improves specific movement symptoms is not completely understood.

Q: What are the active ingredients in Ingrezza?

The active ingredient in Ingrezza is valbenazine .

Q: What are the side effects of Ingrezza?

Common side effects of Ingrezza may include: Somnolence Fatigue Dry mouth Always consult with a healthcare professional about potential side effects.

Q: What drug class is Ingrezza?

Ingrezza belongs to the vesicular monoamine transporter 2 (VMAT2) inhibitor drug class.

Q: What is the dosage of Ingrezza and how do I take it?

How to Take Ingrezza Ingrezza is taken by mouth, usually once per day. It can be taken at any time of day, with or without food. When taking this medication, follow these instructions: Swallow the capsules whole. Do not crush, chew, or open the capsules before swallowing. Try to take the medication at the same time every day to help you remember your dose. Missed Dose If you miss a dose of Ingrezza, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at the same time to make up for a missed one.

Q: Is Ingrezza safe during pregnancy and breastfeeding?

Pregnancy There is currently limited data on the use of Ingrezza in pregnant women. It is not known whether the medication will cause harm to an unborn baby. If you are pregnant or planning to become pregnant, you should discuss your treatment options and any potential risks with your doctor. Breastfeeding It is unknown if Ingrezza passes into breast milk. Because of the risk of serious side effects in a nursing child, it is recommended that you do not breastfeed while taking this medication. If you discontinue the drug, you should wait at least five days after your last dose before breastfeeding.

Q: What forms and strengths does Ingrezza come in?

Available Forms Ingrezza is provided in two oral capsule formats: Oral Capsules: These are standard capsules intended to be swallowed whole. Sprinkle Capsules: These capsules are designed for patients who have difficulty swallowing. They can be swallowed whole or opened and the contents sprinkled onto soft food, such as applesauce or yogurt, before consumption.

Q: What is the FDA approval status of Ingrezza?

FDA Approval History The U.S. Food and Drug Administration (FDA) first approved Ingrezza in April 2017. It was the first drug specifically indicated for the treatment of adults with tardive dyskinesia, a movement disorder often caused by the long-term use of certain psychiatric medications. In August 2023, the FDA expanded its approval to include the treatment of chorea (involuntary movements) associated with Huntington’s disease. Boxed Warning Ingrezza includes a boxed warning, which is the most serious warning required by the FDA. This warning is specific to the treatment of chorea in patients with Huntington’s disease and highlights the following risks: Increased risk of depression Suicidal thoughts or behavior Healthcare providers are advised to monitor patients for any new or worsening symptoms of depression, suicidal ideation, or unusual changes in behavior. The risks of these side effects must be balanced against the clinical need for the medication. Regulatory Status Ingrezza is a prescription-only medication and is not classified as a controlled substance. It is available as an oral capsule and is typically dispensed through specialty pharmacies.

Question 1

What is Ingrezza?

Accepted Answer

This medication works by reducing the amount of certain chemicals in the brain that are involved in signaling muscle activity.

By regulating these chemical levels, it helps to decrease the frequency and severity of uncontrollable physical movements.

Question 2

What is Ingrezza used for?

Accepted Answer

Ingrezza is used to treat tardive dyskinesia, chorea associated with Huntington's disease.

Question 3

How does Ingrezza work?

Accepted Answer

Mechanism of Action

Ingrezza is classified as a vesicular monoamine transporter 2 (VMAT2) inhibitor. It works by blocking a specific protein in the brain called VMAT2, which is responsible for moving certain chemicals into nerve cells.

Regulating Brain Chemicals

The primary chemical affected by this medication is dopamine. Dopamine is a natural substance that helps the brain control muscle movements. In people with certain movement disorders, there may be an imbalance or overactivity of dopamine in the parts of the brain that manage motor function.

By blocking the VMAT2 protein, Ingrezza reduces the amount of dopamine released in the brain. This reduction helps to:

Control involuntary, repetitive body movements.
Manage jerky or irregular motions associated with chorea.

Although the way the drug interacts with the VMAT2 protein is established, the precise mechanism by which it improves specific movement symptoms is not completely understood.

Question 4

What are the active ingredients in Ingrezza?

Accepted Answer

The active ingredient in Ingrezza is valbenazine.

Question 5

What are the side effects of Ingrezza?

Accepted Answer

Common side effects of Ingrezza may include:

Somnolence
Fatigue
Dry mouth

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Ingrezza?

Accepted Answer

Ingrezza belongs to the vesicular monoamine transporter 2 (VMAT2) inhibitor drug class.

Question 7

What is the dosage of Ingrezza and how do I take it?

Accepted Answer

How to Take Ingrezza

Ingrezza is taken by mouth, usually once per day. It can be taken at any time of day, with or without food.

When taking this medication, follow these instructions:

Swallow the capsules whole.
Do not crush, chew, or open the capsules before swallowing.
Try to take the medication at the same time every day to help you remember your dose.

Missed Dose

If you miss a dose of Ingrezza, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at the same time to make up for a missed one.

Question 8

Is Ingrezza safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There is currently limited data on the use of Ingrezza in pregnant women. It is not known whether the medication will cause harm to an unborn baby. If you are pregnant or planning to become pregnant, you should discuss your treatment options and any potential risks with your doctor.

Breastfeeding

It is unknown if Ingrezza passes into breast milk. Because of the risk of serious side effects in a nursing child, it is recommended that you do not breastfeed while taking this medication. If you discontinue the drug, you should wait at least five days after your last dose before breastfeeding.

Question 9

What forms and strengths does Ingrezza come in?

Accepted Answer

Available Forms

Ingrezza is provided in two oral capsule formats:

Oral Capsules: These are standard capsules intended to be swallowed whole.
Sprinkle Capsules: These capsules are designed for patients who have difficulty swallowing. They can be swallowed whole or opened and the contents sprinkled onto soft food, such as applesauce or yogurt, before consumption.

Question 10

What is the FDA approval status of Ingrezza?

Accepted Answer

FDA Approval History

The U.S. Food and Drug Administration (FDA) first approved Ingrezza in April 2017. It was the first drug specifically indicated for the treatment of adults with tardive dyskinesia, a movement disorder often caused by the long-term use of certain psychiatric medications. In August 2023, the FDA expanded its approval to include the treatment of chorea (involuntary movements) associated with Huntington’s disease.

Boxed Warning

Ingrezza includes a boxed warning, which is the most serious warning required by the FDA. This warning is specific to the treatment of chorea in patients with Huntington’s disease and highlights the following risks:

Increased risk of depression
Suicidal thoughts or behavior

Healthcare providers are advised to monitor patients for any new or worsening symptoms of depression, suicidal ideation, or unusual changes in behavior. The risks of these side effects must be balanced against the clinical need for the medication.

Regulatory Status

Ingrezza is a prescription-only medication and is not classified as a controlled substance. It is available as an oral capsule and is typically dispensed through specialty pharmacies.

Question 11

What should I know about Ingrezza and cost?

Accepted Answer

Insurance and Out-of-Pocket Costs

The amount you pay for Ingrezza depends largely on your insurance plan. Most commercial insurance plans, Medicare Part D, and Medicaid provide some level of coverage, though the medication is often placed in a high-cost specialty tier. This may result in significant co-pays or coinsurance requirements.

Specialty Pharmacy Distribution

Ingrezza is generally not available at all retail pharmacies. It is typically distributed through specialty pharmacies that focus on complex medications. These pharmacies often provide additional support, such as help with insurance authorization and delivery coordination.

Financial Assistance Programs

Several options may be available to help reduce the cost of treatment:

Co-pay Savings Cards: Patients with commercial insurance may be eligible for savings cards from the manufacturer that lower out-of-pocket expenses.
Patient Assistance Programs: Non-profit organizations and the drug manufacturer may offer programs for patients who are uninsured or have limited financial resources.
Start Programs: Some programs allow patients to receive a limited supply of the medication for free while waiting for insurance approval.

Ingrezza

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

📚References

Found an Error?

Find Discounts for Ingrezza

Hospitals.net Disclosure